{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-033065","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2025-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.264403+00:00","generated_at":"2026-05-25T09:39:33.160413+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"EyePoint reports Q4 net loss $41.4M; DURAVYU Phase 3 enrollment ahead of expectations","bullets":["Q4 net loss $41.4M ($0.64/share) vs $14.1M loss prior year; revenue $11.6M down from $14.0M.","Full-year net loss $130.9M ($2.32/share) vs $70.8M loss prior year; revenue $43.3M vs $46.0M.","DURAVYU Phase 3 wet AMD trials LUGANO (>50% enrolled) and LUCIA on track; enrollment completion H2 2025, topline data 2026.","Phase 2 VERONA DME trial met endpoints: BCVA +10.3 letters vs +3.0 control; 43% had absence of DME.","Cash $371M as of Dec 31, 2024; runway into 2027; no equity capital plans for 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-033065","json":"https://secwatch.observer/filing/0000950170-25-033065.json","markdown":"https://secwatch.observer/filing/0000950170-25-033065.md","text":"https://secwatch.observer/filing/0000950170-25-033065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017025033065/0000950170-25-033065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017025033065/eypt-20250305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T09:39:33.160413+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}